Analystreport

Tcr2 Therapeutics Inc (NASDAQ: TCRR) was upgraded by analysts at Roth Capital from a "neutral" rating to a "buy" rating.

TCR2 Therapeutics Inc.  (TCRR) 
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am Check Earnings Report